Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma

Sponsor
Janssen Research & Development, LLC
Study ID
NCT05503550
Status
No Longer Available

Conditions

  • Relapsed or Refractory Multiple Myeloma

Eligibility Criteria

Sex
All
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Talquetamab — DRUG
    Talquetamab will be administered subcutaneously (SC).

Study Details

The purpose of this pre-approval access program is to provide talquetamab for the treatment of participants with relapsed or refractory multiple myeloma.

Key Dates

Status verified
Dec 2025

Related Studies